J&J Seeks To Block Generic Topamax

Law360, New York (October 13, 2006, 12:00 AM EDT) -- Johnson & Johnson has asked a New Jersey district judge to prevent the launch of copycat versions of its lucrative epilepsy drug Topamax.

Johnson & Johnson’s preliminary injunction request, filed Thursday, came a month after the U.S. Food and Drug Administration cleared the way for Mylan Laboratories Inc. to sell Topiramate tablets in three dosage strengths—25 mg, 100 mg and 200 mg.

Topamax, which is covered by patents set to expire in 2008, boasts combined annual sales of approximately $1.4 billion for Johnson & Johnson....
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.